Indications
1.1Subcutaneous Fluid Administration
HYLENEX recombinant is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration.
1.2Dispersion and Absorption of Injected Drugs
HYLENEX recombinant is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs.
1.3Subcutaneous Urography
HYLENEX recombinant is indicated as an adjunct in subcutaneous urography for improving resorption of radiopaque agents.
Contraindications
HYLENEX recombinant is contraindicated in patients with known hypersensitivity to hyaluronidase or any of the excipients in HYLENEX recombinant. A preliminary skin test for hypersensitivity to HYLENEX recombinant can be performed. The skin test is made by an intradermal injection of approximately 0.02 mL (3 Units) of a 150 Unit/mL solution. A positive reaction consists of a wheal with pseudopods appearing within 5 minutes and persisting for 20 to 30 minutes and accompanied by localized itching.
Transient vasodilation at the site of the test, i.e., erythema, is not a positive reaction. Discontinue HYLENEX recombinant if sensitization occurs.
Warnings and precautions
5.1Spread of Localized Infection
Hyaluronidase should not be injected into or around an infected or acutely inflamed area because of the danger of spreading a localized infection. Hyaluronidase should not be used to reduce the swelling of bites or stings.
5.2Ocular Damage
Hyaluronidase should not be applied directly to the cornea. It is not for topical use.